India on Monday got its third COVID-19 vaccine after Covishield and Covaxin, as the Centre has approved emergency use of Sputnik V vaccine.
Sputnik V is a COVID-19 vaccine developed by Russia.
Notably, Dr Reddy’s Laboratories, the Hyderabad-based pharmaceutical company, last week sought Centre’s approval for Sputnik V vaccine to be used in India.
The Russian Direct Investment Fund (RDIF) partnered with Dr Reddy’s in September 2020 to conduct clinical trials of Sputnik V in India.
Along with Dr Reddy’s the RDIF partnered with Virchow Biotech Private Limited in March to produce up to 200 million doses per year of Sputnik V in India.
It has also partnered with Stelis Biopharma Pvt Ltd and Panacea Biotec earlier in April as well to produce 200 million and 100 million doses per year of Sputnik V in the country.
India got Sputnik V as the third COVID-19 vaccine as many States in the Country have flagged shortage of Covid-19 vaccine doses.
Sputnik-V claims that it is affordable vaccine and can be “stored at a temperature of +2 to +8°C “.
India is currently using Serum Institute of India (SII)-manufactured Covishield and Bharat Biotech’s Covaxin.
With the second wave of COVID-19 hitting India hard, the approval of Sputnik V as the third vaccine in the Country has come as a major relief.
The vaccine approval will help in boosting supplies that were petering out.
India is currently facing the second wave of COVID-19 pandemic with the number of new cases increasing each day.
On Monday, the country hit a new coronavirus infection record with 1,68,912 new cases, the highest single-day rise so far.